Branded PPI denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Imposes Quantity Limits on Branded PPIs

Aetna applies quantity limits to branded proton pump inhibitors as a utilization-management tool to align dispensing with its interpretation of standard therapeutic use patterns. A quantity-limit denial means your prescription exceeds the amount Aetna will approve per dispensing period under its default policy. These limits are appealable when your prescriber documents a clinical reason your quantity requirement is medically necessary — for example, a chronic high-severity condition, a documented regimen that requires an atypical dosing approach, or a formulary exception supported by clinical evidence.

## Federal Appeal Rights

Quantity-limit denials are subject to the full internal and external appeal process under ACA §2719 (for non-ERISA plans) and ERISA §503 (for self-funded employer plans). After exhausting the internal appeal, you may request independent external review through an IRO. The external-review request window is typically four months from the final internal denial. If your condition makes delay medically risky, expedited external review (72-hour turnaround) is available.

## Appeal Process and Timeline

1. Obtain the denial letter specifying the quantity-limit threshold Aetna applied and the basis for denial. 2. Consult the FDA-approved prescribing label for the branded PPI to confirm the approved dosing range and any provisions for higher-quantity regimens. 3. File an internal appeal with supporting documentation; pre-service appeals require a decision within 30 days. 4. Escalate to external review if the internal appeal is upheld, within four months of the final denial.

## Documentation to Gather

• FDA-approved prescribing label: obtain from DailyMed; confirm the labeled dosing range and any guidance for maintenance versus acute therapy.
• Prescriber medical-necessity letter: a detailed explanation of why the prescribed quantity is clinically required, referencing the patient's diagnosis, severity, and documented therapeutic response.
• Clinical severity records: endoscopy reports, pH monitoring results, symptom-severity documentation, or specialist notes establishing the need for ongoing or higher-intensity therapy.
• Treatment history: records of prior dosing approaches, responses, and the clinical rationale for the current regimen.
• Relevant guideline reference: a citation to the applicable gastroenterology or specialty guideline organization (e.g., ACG, AGA) supporting the prescribed regimen, without quoting specific numbers.

## Criteria-Mapping Strategy

Pull Aetna's Pharmacy Clinical Policy governing quantity limits for this drug class and compare it against the FDA prescribing label. In your appeal, map each quantity-limit criterion to the specific chart evidence that justifies the requested quantity. If the labeled dosing range encompasses the prescribed amount, note that explicitly — Aetna cannot impose a more restrictive limit than the FDA label without a clinical basis documented in its own policy.